Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized double-blind placebo-controlled ascending dose study of KBP-042 in healthy men
NL-OMON42391Phase 1Active, not recruiting
- Sponsor
- KeyBioscience AG
- Start
- Mar 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing KBP-042 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2015; status: active, not recruiting.
02
Drugs
KBP-042
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON42391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42391.